NCT01380457已完成1 期
A Comparative Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 69
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The purpose of this study is to compare the rate and extent of absorption of Dronabinol 10 mg capsules verses Marinol.
详细描述
To compare the plasma levels of dronabinol (delta-9-tetrahydrocannabinol)and the principle active metabolite 11-OH-delta-9-tetrahydrocannabinol levels produced after administration of the test formulation with those produced after administration of a marketed reference product, under fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers, 18 - 55 years of age
- •Subjects must be within 18 to 29.9 kilograms/m2 per the BMI
- •General good health as determined by medical history and physical examination within 30 days prior to the start of the study
- •Blood chemistry, hematology, and urinalysis tests will be performed within 30 days prior to the start of the study
- •No participation in an investigational drug study or donation of blood within 30 days prior to the start of the study
- •At screening, subjects must have blood pressure and pulse rate within specified ranges
- •No grapefruit juice or grapefruit-containing products for at least 72 hours prior to drug administration, each period. Subjects will be queried at check-in each period on consumption of grapefruit juice or grapefruit containing products. Results will be recorded and reported in the final report.
- •No alcohol consumption for at least 24 hours prior to drug administration, each period
- •No caffeine or xanthine consumption for 48 hours prior prior to drug administration, each period
- •No prescription drugs (excluding hormonal contraceptives) within 14 days prior to drug administration, each period
- •Subjects should refrain from taking OTC preparations, and/or nutritional supplements within 7 days prior to drug administration, each period. Subjects shall refrain from taking herbal remedies within 14 day prior to drug administration, and throughout the study periods
- •Female subjects must not be pregnant or nursing; and must be surgically sterile; one year post-menopausal; or on hormonal contraceptive agents), a diaphragm or condom with spermicidal foam or jelly, or IUD for at least 3 months prior to drug administration and agree to use the same method of contraception for at least 1 month after the last drug administration
- •Negative serum pregnancy test at screening and negative urine pregnancy test prior to drug administration, each period
- •Negative HIV 1, hepatitis B surface antigen, an urine screen for drugs of abuse within 30 days prior to the start of the study
排除标准
- •Disease or condition that could impact interpretation of study results or a condition which treatment would be contraindicated per currently approved product labeling
- •Subjects had any of the following conditions:
- •used any prescription or OTC medication within 14 days of study initiation
- •a positive urine test for illicit drugs
- •participated in a clinical investigation within the past 30 days
- •had clinically significant allergies to drugs or foods, ot
- •any condition that might place them at increased risk of complications
研究组 & 干预措施
A
Experimental
Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
干预措施: Dronabinol (Drug)
B
Active Comparator
Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
干预措施: Marinol (Drug)
结局指标
主要结局
Bioequivalence
To conclude bioequivalence; 90% geometric confidence interval was contained within the limits 0.8 to 1.25.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting ConditionsHealthyNCT00974012Teva Pharmaceuticals USA24
已完成
1 期
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.HealthyNCT01260922Teva Pharmaceuticals USA26
已完成
1 期
Donepezil 10 mg Tablets Under Fed ConditionsHealthyNCT01439243Teva Pharmaceuticals USA26
已完成
1 期
Donepezil 10 mg Tablets Under Fasting ConditionsHealthyNCT01439230Teva Pharmaceuticals USA36
已完成
1 期
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting ConditionsHealthyNCT01260948Teva Pharmaceuticals USA26